Hirsch Mehta, MD
Advanced Heart Failure and Transplant Cardiology · San Diego, CANPI 1407099799
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $422,524 of the $494,085 with a category attached, or 85.5%. It is spread thinly across 50 manufacturers, the largest accounting for just 23.5%. Among advanced heart failure and transplant cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,246 payments — averaging $396.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$116K
- Merck$68K
- Boehringer Ingelheim$56K
- Boston Scientific$37K
- Alnylam Pharmaceuticals Inc.$35K
- E.r. Squibb & Sons, L.L.C.$30K
- plus $152K from 44 others
Across 67 payments — averaging $5240.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$169K
- Boehringer Ingelheim Pharma GmbH & Co.kg$75K
- Boehringer Ingelheim International GmbH$59K
- Janssen Research & Development, LLC$23K
- Amgen$19K
- Merck$6K
What the payments were for
- Consulting fees$35,8867%
- Speaking & faculty fees$422,52486%
- Travel & lodging$16,6673%
- Food & beverage$18,9044%
- Education$1060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$106,873
- UPTRAVI$98,471
- OPSUMIT$91,401
- JARDIANCE$72,203
- AMVUTTRA$33,430
- Adempas$26,533
- WATCHMAN Access System$20,878
- CAMZYOS$19,515
- VYNDAQEL$19,028
- FARXIGA$16,368
- Watchman$15,624
- Attruby$13,505
- TEGSEDI$12,065
- ELIQUIS$10,963
- MitraClip System$3,625
- WAINUA$1,074
- Impella$268
- CardioMEMS HF System$254
- Quadra Assura CRT Defibrillator$172
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$168
How this compares
$494,085 in reported general payments places this provider in the 95th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 51 | $711,957 |
| AdempasRiociguat | 54 | $686,572 |
| VyndamaxTafamidis | 26 | $642,966 |
| UptraviSelexipag | 33 | $637,418 |
| CamzyosMavacamten | 51 | $411,401 |
| EliquisApixaban | 174 | $236,294 |
| EntrestoSacubitril/Valsartan | 69 | $116,020 |
| JardianceEmpagliflozin | 78 | $111,833 |
| XareltoRivaroxaban | 29 | $46,010 |
| FarxigaDapagliflozin Propanediol | 23 | $37,609 |
| Repatha SureclickEvolocumab | 20 | $27,271 |
| VascepaIcosapent Ethyl | 26 | $18,464 |
| Praluent PenAlirocumab | 12 | $12,606 |
| Rosuvastatin Calcium | 431 | $9,755 |
| Repatha PushtronexEvolocumab | 11 | $8,783 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $115,866 | $1,349,37584 claims |
| PfizerVyndamax, Eliquis | $22,516 | $879,261200 claims |
| BayerAdempas | $29,782 | $686,57254 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $29,976 | $411,40151 claims |
| NovartisEntresto | $418 | $116,02069 claims |
| Boehringer IngelheimJardiance | $55,734 | $111,83378 claims |
| Johnson & JohnsonXarelto | $249 | $46,01029 claims |
| AstraZenecaFarxiga | $22,863 | $37,60923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in San Diego
- Marcus UreySan Diego$341K
- Barry GreenbergSan Diego$270K
- Brian JaskiSan Diego$235K
- Ajay SrivastavaSan Diego$203K
- Jorge Silva EncisoSan Diego$164K
- Burhan MohamedaliSan Diego$154K
- Hao TranSan Diego$147K
- Justin ParizoSan Diego$24K
- Eric AdlerSan Diego$24K
- Peter HoaglandSan Diego$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.